In this Review:
Evaluating neoadjuvant therapy in locally-advanced breast caner
Comparing therapies for HER2- positive HR+ve early breast cancer following NAC
A phase III trial of adjuvant capecitabine after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)
The impact of adjuvant denosumab on bone health and disease-free survival
The addition of carboplatin to neoadjuvant chemotherapy in patients with TNBC
Ten year follow-up of BCIRG-006 in early HER2+ve BC
Predicting the efficacy of buparlisib plus fulvestrant in postmenopausal HR+/HER2 patients
Trastuzumab emtansine versus treatment of physician’s choice – a phase III study
Pembrolizumab in patients with PD-L1-positive, ER+/HER2-negative advanced BC
High risk premenopausal luminal A BC patients derive no benefit from adjuvant chemotherapy – a prospective-retrospective analysis
Please login below to download this issue (PDF)